Abstract
Background and Purpose: Hypertension is a common medical complication in acute stroke and is associated with a poor outcome. However, no large trials have assessed the effect of lowering blood pressure (BP) on outcome, and it remains unclear how BP should be managed in acute stroke. We assessed, in a double-blind randomised controlled trial, whether the nitric oxide (NO) donor glyceryl trinitrate (GTN, a known systemic and cerebral vasodilator), would lower BP and alter platelet function. Methods: Thirty-seven patients with recent (<5 days) ischaemic or haemorrhagic stroke were randomised by minimisation to 12 days of daily treatment with transdermal GTN or matching placebo patches. Twenty-four-hour ambulatory BP was measured before and during GTN treatment at days 0, 1 and 8. Platelet aggregation and expression of adhesion molecules were assessed at the same time points. Functional outcome (Rankin scale) and case fatality were assessed at 3 months. Analysis was by intention-to-treat. Results: GTN significantly lowered BP by 13.0/5.2 mm Hg at day 1 and 9.3/5.0 mm Hg at day 8. The lesser reduction at day 8 than day 1 suggests that tolerance to GTN was developing. Non-significant falls of 0.9/0.6 and 3.8/0.0 mm Hg occurred at days 1 and 8, respectively, in the placebo group. GTN had no effect on heart rate, or platelet aggregation or expression of platelet adhesion molecules, including glycoproteins Ia, Ib, IIIa and P-selectin. Additionally, GTN did not alter case fatality or dependency, although the study was not powered for these outcomes. Conclusions: Transdermal GTN, an NO donor, lowered BP by 5–8%, a clinically significant and relevant, but not excessive, degree in patients with acute stroke. However, GTN had no effect on platelet aggregation or expression of adhesion molecules. Since NO donors increase cerebral blood flow in patients with acute ischaemic stroke, GTN may be an appropriate drug for testing the effect of lowering BP on functional outcome.
References
1.
Britton M, Carlsson A, de Faire U: Blood pressure course in patients with acute stroke and matched controls. Stroke 1986;17:861–864.
2.
Carlberg B, Asplund K, Hagg E: The prognostic value of admission blood pressure in patients with acute stroke. Stroke 1993;24:1372–1375.
3.
Robinson T, Waddington A, Ward-Close S, Taub N, Potter J: The predictive role of 24-hour compared to casual blood pressure levels on outcome following acute stroke. Cerebrovasc Dis 1997;7:264–272.
4.
Bath FJ, Bath PMW: What is the correct management of blood pressure in acute stroke? The Blood Pressure in Acute Stroke Collaboration. Cerebrovasc Dis 1997;7:205–213.
5.
Blood Pressure in Acute Stroke Collaboration (BASC): Interventions for deliberately altering blood pressure in acute stroke (Cochrane Review). Oxford, Cochrane Library, Update Software, 2000.
6.
Fagan SC, Gengo FM, Bates V, Levine SR, Kinkel WR: Effect of nimodipine on blood pressure in acute ischemic stroke in humans. Stroke 1988;19:401–402.
7.
Lisk DR, Grotta JC, Lamki LM, et al: Should hypertension be treated after acute stroke. A randomised controlled trial using single photon emission computed tomography. Arch Neurol 1993;50:855–862.
8.
Uzner N, Ozdemir G, Gucuyener D: The interaction between nimodipine and systemic blood pressure and pulse rate. WHO Consensus Conf Helsingborg 1995.
9.
Dyker AG, Grosset DG, Lees K: Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke 1997;28:580–583.
10.
Rordorf G, Cramer SC, Efird JT, Schwamm LH, Buonanno F, Koroshetz WJ: Pharmacological elevation of blood pressure in acute stroke. Clinical effects and safety. Stroke 1997;28:2133–2138.
11.
Dandapani BK, Suzuki S, Kelley RE, Reyes-Iglesias Y, Duncan R: Relation between blood pressure and outcome in intracerebral haemorrhage. Stroke 1995;26:21–24.
12.
Wahlgren NG, MacMahon DG, de Keyser J, Indredavik B, Ryman T, INWEST Study Group: Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovasc Dis 1994;4:204–210.
13.
Squire IB, Lees KR, Pryse-Phillips W, Kertesz A, Bamford J: The effects of lifarizine in acute cerebral infarction: A pilot study. Cerebrovasc Dis 1996;6:156–160.
14.
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute stroke. N Engl J Med 1995;333:1581–1587.
15.
Brott T, Lu M, Kothari R, et al: Hypertension and its treatment in the NINDS rt-PA stroke trial. Stroke 1998;29:1504–1509.
16.
Slyter H: Ethical challenges in stroke research. Stroke 1998;29:1725–1729.
17.
Zhang F, Iadecola C: Reduction of focal cerebral ischemic damage by delayed treatment with nitric oxide donors. J Cereb Blood Flow Metab 1994;14:574–580.
18.
Butterworth RJ, Cluckie A, Jackson SHD, Buxton-Thomas M, Bath PMW: Pathophysiological assessment of nitric oxide (given as sodium nitroprusside) in acute ischaemic stroke. Cerebrovasc Dis 1998;8:158–165.
19.
Bath PMW, Butterworth RJ, Soo J, Kerr JE: The Kings College Hospital Acute Stroke Unit. J R Coll Phys (London) 1996;30:13–17.
20.
Bath PMW, Butterworth RJ, Soo J, Kerr J: Do acute stroke units improve care? Cerebrovasc Dis 1996;6:346–349.
21.
Wolff M, Luckow V: In vitro and in vivo-release of nitroglycerin from a new transdermal therapeutic system. Pharm Res 1985;1:23–29.
22.
Bamford J, Sandercock P, Dennis M, Burn J, Warlow C: Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521–1526.
23.
Sharp DS, Benowitz NL, Bath PMW, Martin JF, Beswick AD, Elwood PC: Cigarette smoking sensitizes and desensitizes impedance-measured ADP-induced platelet aggregation in whole blood. Thromb Haemost 1995;74:730–735.
24.
Rankin J: Cerebral vascular accidents in patients over the age of 60. 2. Prognosis. Scot Med J 1957;2:200–215.
25.
Lavin P: Management of hypertension in patients with acute stroke. Arch Intern Med 1986;146:66–68.
26.
O’Connell JE, Gray GS: Treating hypertension after stroke. Br Med J 1994;308:1523–1524.
27.
Abrams J: Nitrates. Cardiovasc Pharmacol 1988;72:1–35.
28.
Needleman P, Jakschik B, Johnson EM: Sulfhydryl requirement for relaxation of vascular smooth muscle. J Pharm Exp Ther 1973;187:324–331.
29.
Parker JO, Fung HL: Transdermal nitroglycerin in angina pectoris. Am J Cardiol 1984;54:471–476.
30.
Gruppo Italiano per lo studio della sorpavvivenza nell’infarto miocardio GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115–1122.
31.
Benjamin N, Dutton JAE, Ritter JM: Human vascular smooth muscle cells inhibit platelet aggregation when incubated with glyceryl trinitrate: Evidence for generation of nitric oxide. Br J Pharmacol 1991;102:847–850.
32.
Bath PMW: The effect of nitric oxide-donating vasodilators on monocyte chemotaxis and intracellular cGMP concentrations in vitro. Eur J Clin Pharmacol 1993;45:53–58.
33.
Andrews R, May JA, Vickers J, Heptinstall S: Inhibition of platelet aggregation by transdermal glyceryl trinitrate. Br Heart J 1994;72:575–579.
34.
Hogan JC, Lewis MJ, Henderson AH: Glyceryl trinitrate and platelet aggregation: Effects of N-acetyl-cysteine. Br J Clin Pharmacol 1989;27:617–619.
35.
Ritter JM, Benjamin N, Doktor HS, et al: Effects of a selective thromboxane receptor antagonist (GR3219B) and of glyceryl trinitrate on bleeding time in man. Br J Clin Pharmacol 1990;29:431–436.
36.
Booth BP, Jacob S, Bauer JA, Fung HL: Sustained antiplatelet properties of nitroglycerin during hemodynamic tolerance in rats. J Cardiovasc Pharmacol 1996;28:432–438.
37.
Dahl A, Russell D, Nyberg-Hansen R, Rootwelt K: Effect of nitroglycerin on cerebral circulation measured by transcranial Doppler and SPECT. Stroke 1989;20:1733–1736.
38.
Zhang F, Iadecola C: Nitroprusside improves blood flow and reduces brain damage after focal ischaemia. Clin Neurosci Neuropathol 1993;4:559–562.
39.
Zhang F, White JG, Iadecola C: Nitric oxide donors increase blood flow and reduce brain damage in focal ischemia: Evidence that nitric oxide is beneficial in the early stages of cerebral ischemia. J Cerebral Blood Flow Metab 1994;14:217–226.
40.
Zhang F, Casey RM, Ross ME, Iadecola C: Aminoguanidine ameliorates and L-arginine worsens brain damage from intraluminal middle cerebral artery occlusion. Stroke 1996;27:317–323.
41.
Escott KJ, Beech JS, Haga KK, Williams SCR, Meldrum BS, Bath PMW: Cerebroprotective effect of the nitric oxide synthase inhibitors, 1-(2-trifluoromethylphenyl) imidazole (TRIM) and 7-nitro indazole, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1998;18:281–287.
42.
Samdani AF, Dawson TM, Dawson VL: Nitric oxide synthase in models of focal ischemia. Stroke 1997;28:1283–1288.
43.
Lipton SA, Chol Y-B, Pan Z-H, et al: A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 1993;364:626–632.
44.
International Stroke Trial Collaborative Group: The International Stroke Trial (IST); a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997;349:1569–1581.
45.
CAST (Chinese Acute Stroke Trial) Collaborative Group: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997;349:1641–1649.
46.
Bath PMW, Hassall DG, Gladwin A-M, Palmer RMJ, Martin JF: Nitric oxide and prostacyclin. Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arteriosclerosis Thromb 1991;11:254–260.
47.
Bath PMW, Bath FJ, Smithard DG: Interventions for dysphagia in acute stroke (Cochrane Review). Oxford, Cochrane Library, Update Software, 2000.
48.
Bath PMW, Pathansali R, Iddenden R, Bath FJ: The effect of nitric oxide, given as transdermal glyceryl trinitrate, on blood pressure in acute stroke (abstract). Cerebrovasc Dis 1999;9(suppl 1):101.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
